Treatment of new onset type 1 diabetes with teplizumab: successes and pitfalls in development (Q38187146)

30 August 2017

Treatment of new onset type 1 diabetes with teplizumab: successes and pitfalls in development (English)

1 reference

30 August 2017

0 references

language of work or name

English

0 references

publication date

1 March 2014

1 reference

Expert Opinion on Biological Therapy

30 August 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24517093%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

volume

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24517093%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

page(s)

377-385

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24517093%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24517093%20AND%20SRC:MED&resulttype=core&format=json

Type I diabetes mellitus. A chronic autoimmune disease

4 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.881797

Type 1 diabetes: translating mechanistic observations into effective clinical outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.881797

Immune therapy for type 1 diabetes mellitus-what is unique about anti-CD3 antibodies?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.881797

Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.881797

Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomised, double-blind, placebo-controlled phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.881797

Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.881797

GAD65 vaccination: 5 years of follow-up in a randomised dose-escalating study in adult-onset autoimmune diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.881797

Etanercept treatment in children with new-onset type 1 diabetes: pilot randomized, placebo-controlled, double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.881797

Plasmid-encoded proinsulin preserves C-peptide while specifically reducing proinsulin-specific CD8⁺ T cells in type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.881797

Adaptive TGF-beta-dependent regulatory T cells control autoimmune diabetes and are a privileged target of anti-CD3 antibody treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.881797

Unique role of CD4+CD62L+ regulatory T cells in the control of autoimmune diabetes in T cell receptor transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.881797

TGF-beta-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.881797

Induction of allograft tolerance by monoclonal CD3 antibodies: a matter of timing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.881797

Anti-CD3 therapy promotes tolerance by selectively depleting pathogenic cells while preserving regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.881797

Delayed anti-CD3 therapy results in depletion of alloreactive T cells and the dominance of Foxp3+ CD4+ graft infiltrating cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.881797

Control of TH17 cells occurs in the small intestine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.881797

Teplizumab induces human gut-tropic regulatory cells in humanized mice and patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.881797

HuM291, a humanized anti-CD3 antibody, is immunosuppressive to T cells while exhibiting reduced mitogenicity in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.881797

In vitro characterization of five humanized OKT3 effector function variant antibodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.881797

Anti-CD3 clinical trials in type 1 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.881797

Humanized, nonmitogenic OKT3 antibody, huOKT3 gamma(Ala-Ala): initial clinical experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.881797

Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.881797

A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.881797

Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb Teplizumab preserves insulin production for up to 5 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.881797

Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.881797

Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.881797

Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.881797

Teplizumab treatment may improve C-peptide responses in participants with type 1 diabetes after the new-onset period: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.881797

Immune therapy and β-cell death in type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.881797

TCR stimulation with modified anti-CD3 mAb expands CD8+ T cell population and induces CD8+CD25+ Tregs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.881797

Acquisition of regulatory function by human CD8(+) T cells treated with anti-CD3 antibody requires TNF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.881797

NKG2A is a marker for acquisition of regulatory function by human CD8+ T cells activated with anti-CD3 antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.881797

Synergistic reversal of type 1 diabetes in NOD mice with anti-CD3 and interleukin-1 blockade: evidence of improved immune regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.881797

Reversal of autoimmune diabetes by restoration of antigen-specific tolerance using genetically modified Lactococcus lactis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.881797

Anti-CD3 and nasal proinsulin combination therapy enhances remission from recent-onset autoimmune diabetes by inducing Tregs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.881797

C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve beta-cell function: report of an ADA workshop, 21-22 October 2001.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.881797

Beta-cell function and the development of diabetes-related complications in the diabetes control and complications trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.881797

Effects of Cyclosporine Immunosuppression in Insulin-Dependent Diabetes Mellitus of Recent Onset

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.881797

Fall in C-peptide during first 2 years from diagnosis: evidence of at least two distinct phases from composite Type 1 Diabetes TrialNet data

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.881797

Plasticity of human regulatory T cells in healthy subjects and patients with type 1 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.881797

Rituximab, B-Lymphocyte Depletion, and Preservation of Beta-Cell Function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.881797

10.1517/14712598.2014.881797

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24517093%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

1 reference